Ergomed plc will announce its interim results for the six months ended 30 June 2018 on Wednesday 19th September 2018.
London, UK – 14 September 2018-- ErgoMed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19th September 2018.
Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief Financial Officer, will host a presentation and conference call for analysts at 8:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.
ENDS
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 503 205 | |
Stephen Stamp (Chief Executive Officer) Stuart Jackson (Chief Financial Officer) | ||
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
| Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
| James Black (Joint Broker) | ||
| Consilium Strategic Communications – for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
Chris Gardner / Mary-Jane Elliott Matthew Neal / Olivia Manser | ergomed@consilium-comms.com | |
| MC Services – for Continental European enquiries | Tel: +49 211 5292 5222 | |
| Anne Hennecke | ||
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
